|
| 36828585 | Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica. | Ann Rheum Dis | 2024 |
| 37625672 | Subclinical giant cell arteritis in polymyalgia rheumatica: Concurrent conditions or a common spectrum of inflammatory diseases? | Autoimmun Rev | 2024 |
| 37550004 | EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update. | Ann Rheum Dis | 2024 |
| 33268441 | Response to: 'Correspondence on 'Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia'' by Evangelatos <i>et al</i>. | Ann Rheum Dis | 2023 |
| 37308659 | Disease stratification in GCA and PMR: state of the art and future perspectives. | Nat Rev Rheumatol | 2023 |
| 36637182 | An international survey of current management practices for polymyalgia rheumatica by general practitioners and rheumatologists. | Rheumatology (Oxford) | 2023 |
| 36600183 | The provisional OMERACT ultrasonography score for giant cell arteritis. | Ann Rheum Dis | 2023 |
| 35961758 | Expression of interleukin-6 in synovial tissue of patients with polymyalgia rheumatica. | Ann Rheum Dis | 2023 |
| 32759255 | Response to: 'Diagnostic value of ultrasound halo count and Halo Score in giant cell arteritis: a retrospective study from routine care' by Molina Collada <i>et al</i>. | Ann Rheum Dis | 2022 |
| 36660427 | A hybrid approach to study large conformational transitions of biomolecules from single particle XFEL diffraction data. | Front Mol Biosci | 2022 |
| 36659985 | Explicit versus implicit consideration of binding partners in protein-protein complex to elucidate intrinsic dynamics. | Biophys Rev | 2022 |
| 36032100 | Contribution of pathogenic T helper 1 and 17 cells to bursitis and tenosynovitis in polymyalgia rheumatica. | Front Immunol | 2022 |
| 33616316 | Long-Term Efficacy and Safety of Leflunomide in Large-Vessel Giant Cell Arteritis: A Single-Center, 10-Year Experience. | J Clin Rheumatol | 2022 |
| 35264321 | Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. | Ann Rheum Dis | 2022 |
| 35234846 | Comment on: Diagnosing giant cell arteritis: a comprehensive practical guide for the practicing rheumatologist. | Rheumatology (Oxford) | 2022 |
| 34718434 | New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension. | Rheumatology (Oxford) | 2022 |
| 32571871 | Response to: 'Diagnostic accuracy of novel ultrasonographic halo score for giant cell arteritis: methodological issues' by Ghajari and Sabour. | Ann Rheum Dis | 2022 |
| 32651193 | Response to: ''Halo Score': missing large vessel giant cell arteritis- do we need a modified 'Halo Score?'' by Chattopadhyay and Ghosh. | Ann Rheum Dis | 2022 |
| 32550671 | Biologic agents and small-molecule inhibitors in systemic autoimmune conditions: an update. | Pol Arch Intern Med | 2021 |
| 33854129 | Detecting network anomalies using Forman-Ricci curvature and a case study for human brain networks. | Sci Rep | 2021 |
| 34514295 | Role of the halo sign in the assessment of giant cell arteritis: a systematic review and meta-analysis. | Rheumatol Adv Pract | 2021 |
| 34422905 | Reconstruction of Three-Dimensional Conformations of Bacterial ClpB from High-Speed Atomic-Force-Microscopy Images. | Front Mol Biosci | 2021 |
| 31826856 | Response to: 'Correspondence to 'Slope sign': a feature of large vessel vasculitis?' by Milchert <i>et al</i>. | Ann Rheum Dis | 2021 |
| 33355340 | Ultrasonographic Halo Score in giant cell arteritis: association with intimal hyperplasia and ischaemic sight loss. | Rheumatology (Oxford) | 2021 |
| 33232471 | Comment on: Diagnostic accuracy of ultrasound for detecting large-vessel giant cell arteritis using FDG PET/CT as the reference. | Rheumatology (Oxford) | 2021 |
| 32332274 | Excellent Response to Leflunomide in a Case of Large-Vessel Giant Cell Arteritis Demonstrated Simultaneously by Clinical, Laboratory, Ultrasound, and Positron Emission Tomography/Computed Tomography Parameters. | J Clin Rheumatol | 2021 |
| 31270110 | 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. | Ann Rheum Dis | 2020 |
| 31970410 | British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. | Rheumatology (Oxford) | 2020 |
| 31970405 | British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. | Rheumatology (Oxford) | 2020 |
| 31900304 | Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia. | Ann Rheum Dis | 2020 |
| 31775013 | The role of vascular ultrasound in managing giant cell arteritis in ophthalmology. | Surv Ophthalmol | 2020 |
| 31848610 | The impact of disease extent and severity detected by quantitative ultrasound analysis in the diagnosis and outcome of giant cell arteritis. | Rheumatology (Oxford) | 2020 |
| 33026077 | Comment on: British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: reply. | Rheumatology (Oxford) | 2020 |
| 33161376 | Efficacy and safety of tocilizumab in giant cell arteritis: a single centre NHS experience using imaging (ultrasound and PET-CT) as a diagnostic and monitoring tool. | RMD Open | 2020 |
| 33241175 | Polymyalgia rheumatica and large vessel vasculitis: a case report. | Rheumatol Adv Pract | 2020 |
| 32994361 | Probability-based algorithm using ultrasound and additional tests for suspected GCA in a fast-track clinic. | RMD Open | 2020 |
| 32821876 | Halo score (temporal artery, its branches and axillary artery) as a diagnostic, prognostic and disease monitoring tool for Giant Cell Arteritis (GCA). | BMC Rheumatol | 2020 |
| 32844378 | A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis. | Rheumatol Ther | 2020 |
| 32393983 | Early variation of ultrasound halo sign with treatment and relation with clinical features in patients with giant cell arteritis. | Rheumatology (Oxford) | 2020 |
| 30156979 | The Collaborative Ocular Tuberculosis Study (COTS)-1: A Multinational Description of the Spectrum of Choroidal Involvement in 245 Patients with Tubercular Uveitis. | Ocul Immunol Inflamm | 2020 |
| 31472175 | Reconstruction of low-resolution molecular structures from simulated atomic force microscopy images. | Biochim Biophys Acta Gen Subj | 2020 |
| 29261089 | The Collaborative Ocular Tuberculosis Study (COTS)-1 Report 3: Polymerase Chain Reaction in the Diagnosis and Management of Tubercular Uveitis: Global Trends. | Ocul Immunol Inflamm | 2019 |
| 31673416 | Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis. | RMD Open | 2019 |
| 32799976 | The association of pain and stiffness with fatigue in incident polymyalgia rheumatica: baseline results from the polymyalgia rheumatica cohort study. | Prim Health Care Res Dev | 2019 |
| 31531960 | Circulating interleukin-6 as a biomarker in a randomized controlled trial of modified-release prednisone vs immediate-release prednisolone, in newly diagnosed patients with giant cell arteritis. | Int J Rheum Dis | 2019 |
| 31608410 | Free-energy landscape of molecular interactions between endothelin 1 and human endothelin type B receptor: fly-casting mechanism. | Protein Eng Des Sel | 2019 |
| 31519653 | 'Slope sign': a feature of large vessel vasculitis? | Ann Rheum Dis | 2019 |
| 30898854 | Identification of an activated neutrophil phenotype in polymyalgia rheumatica during steroid treatment: a potential involvement of immune cell cross-talk. | Clin Sci (Lond) | 2019 |
| 30898837 | 2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis. | Ann Rheum Dis | 2019 |
| 30835950 | Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab. | Arthritis Rheumatol | 2019 |